Pfizer Signs an Exclusive Worldwide License Agreement with Akcea for its AKCEA-ANGPTL3-L(Rx)

Pfizer Signs an Exclusive Worldwide License Agreement with Akcea for its AKCEA-ANGPTL3-L(Rx)

Shots:

  • Akcea and Ionis to receive $250M, up to $1.3B as development, regulatory and commercial milestone with royalties on global sales of AKCEA-ANGPTL3-L(Rx) splitting equally b/w the companies. Akcea will settle its $125M obligations to Ionis in Akcea common stock
  • Pfizer will be responsible for all development and regulatory activities and costs after P-II study. Prior to a regulatory filing for approval, Akcea has the option to participate in commercialization activities with Pfizer in the US and other additional markets on pre-defined terms and based on meeting pre-defined criteria
  • AKCEA-ANGPTL3-LRx is an investigational antisense therapy being developed to treat patients with CV and metabolic diseases, designed to reduce the (ANGPTL3) protein in the liver, currently being evaluated in P-II study in patients with T2D, hypertriglyceridemia & NAFLD

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pfizer